Poniard Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the development of novel immunotherapies to treat addiction and other central nervous system disorders. Since its founding in the early 2000s, Poniard has pursued a proprietary vaccine platform designed to induce targeted antibody responses against specific drugs of abuse. The company’s lead programs aim to address the unmet medical need for safe and effective treatments for opioid and methamphetamine dependence, with preclinical and early‐stage clinical studies supporting the potential for long‐lasting efficacy and a favorable safety profile.
Leveraging its core technology, Poniard is advancing multiple product candidates through the clinical pipeline. The company’s flagship asset is a conjugate vaccine targeting opioids, which has demonstrated the ability to reduce drug‐seeking behavior in animal models. Additional programs include vaccines directed against methamphetamine and other stimulants that have shown promising immunogenicity. Poniard collaborates with academic research institutions and contract research organizations across North America to conduct its preclinical and clinical studies, ensuring compliance with FDA regulatory guidelines.
Headquartered in Fremont, California, Poniard Pharmaceuticals operates a research hub in the San Francisco Bay Area and maintains strategic partnerships with manufacturing facilities in the United States. The company’s leadership team is led by Chief Executive Officer Mark B. Foley, whose experience spans over two decades in specialty pharmaceuticals and biotech development. President and Chief Scientific Officer Dr. Kristin C. Ireland brings extensive expertise in immunology and vaccine science, guiding the design and execution of Poniard’s research programs.
With a focus on advancing its vaccine candidates through Phase 1 and beyond, Poniard is committed to addressing the global opioid epidemic and expanding its pipeline to other central nervous system indications. The company continues to engage with regulatory agencies, potential commercial partners and patient advocacy groups to support future late‐stage clinical trials and, ultimately, broad patient access to its innovative immunotherapies.
AI Generated. May Contain Errors.
Free PARD Stock Alerts